brand logo

Am Fam Physician. 2021;103(11):698-700

This clinical content conforms to AAFP criteria for CME.

Author disclosure: No relevant financial affiliations.

Key Points for Practice

• Structured diabetes self-management education programs are recommended because they improve self-efficacy and clinical outcomes.

• First-line antiglycemic treatment for type 2 diabetes and CKD with eGFR as low as 30 mL per minute per 1.73 m2 should include metformin and an SGLT2 inhibitor to improve cardiovascular outcomes and limit CKD progression.

• ACE inhibitor or ARB treatment should be maximized in patients who have diabetes with albuminuria and hypertension unless complicated by symptomatic hypotension, uncontrolled hyperkalemia, or more than a 30% increase in creatinine level.

From the AFP Editors

Diabetes mellitus affects more than 450 million people globally, which could increase to more than 700 million people by 2045. Up to 40% of cases of diabetes are complicated by chronic kidney disease (CKD), with persistent abnormalities of kidney function demonstrated by elevated urine albumin excretion or reduced estimated glomerular filtration rate (eGFR). The Kidney Disease: Improving Global Outcomes (KDIGO) group, an international organization dedicated to nephrology clinical practice guidelines, has developed a new guideline for management of diabetes with CKD.

Team-Based Care

People with diabetes and CKD have high risks of CKD progression, cardiovascular disease (CVD), and mortality, which can be reduced with a comprehensive approach to lifestyle and risk factor management in combination with appropriate pharmacotherapy (Figure 1). Optimal care includes primary care, cardiology, nephrology, endocrinology, psychology, nutrition, and disease management nursing support.

Self-Management Education

Structured education in diabetes self-management is recommended for people with diabetes and CKD because education improves long-term clinical outcomes and quality of life. Group-based education programs improve A1C level, fasting blood glucose level, body weight, self-efficacy, and patient satisfaction.

Dietary and Lifestyle Management

Dietary advice for people with diabetes and CKD should include consumption of a balanced, healthy diet that is high in vegetables, fruits, whole grains, fiber, legumes, plant-based proteins, unsaturated fats, and nuts and lower in processed meats, refined carbohydrates, and sweetened beverages. Nutritional recommendations may have to be adjusted for conditions such as hyperkalemia as well as personal and cultural preferences. Daily dietary protein intake should be maintained at 0.8 g per kg, which is recommended for all people. Neither higher- nor lower-protein diets are advised, although people on dialysis should have daily dietary protein intake of 1.0 to 1.2 g per kg to offset muscle catabolism. Sodium intake should be limited to less than 2 g per day or less than 5 g of sodium chloride.

Lower levels of physical activity are common and associated with worse clinical outcomes. Moderate-intensity physical activity for at least 150 minutes per week and reduction in sedentary activity are recommended.

In addition to further increasing cardiovascular risk, cigarette smoking is associated with kidney disease progression, and patients should be advised to quit smoking.

Glycemic Treatment

For people with type 2 diabetes and CKD with an eGFR 30 mL per minute per 1.73 m2 or higher, metformin and sodium-glucose cotransporter 2 (SGLT2) inhibitors, in combination, are recommended for first-line medical treatment because they improve glycemic control outcomes. Metformin limits weight gain and reduces cardiovascular events, whereas the SGLT2 inhibitor improves cardiovascular outcomes and limits kidney disease progression.

Metformin is safe in patients with an eGFR above 45 mL per minute per 1.73 m2 unless risk for acute kidney injury is high. The dose of metformin should be reduced when eGFR is less than 45 mL per minute per 1.73 m2 and discontinued when eGFR is less than 30 mL per minute per 1.73 m2 or in people treated with dialysis.

SGLT2 inhibitor use can cause a reversible decline in eGFR that usually does not require stopping the medication. The SGLT2 inhibitor can be continued with an eGFR below 30 mL per minute per 1.73 m2 if well-tolerated and dialysis is not imminent. SGLT2 inhibitor use is associated with genital mycotic infections and rare diabetic ketoacidosis. Limb amputations were increased in one trial.

The guidelines recommend treatment with a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist in patients with type 2 diabetes who have not achieved glycemic goals despite use of metformin and an SGLT2 inhibitor or who are unable to use those medications. Some of the GLP-1 receptor agonists have a beneficial effect in reducing cardiovascular events. GLP-1 receptor agonist trials are safe with an eGFR as low as 15 mL per minute per 1.73 m2, where they appear to reduce albuminuria and preserve eGFR. They should not be prescribed with dipeptidyl peptidase-4 inhibitors. They can be used with a sulfonylurea or insulin, although the doses of these medications may need to be reduced.

Already a member/subscriber?  Log In


From $145
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits/year
  • AAFP app access
  • Print delivery available

Issue Access

  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available

Article Only

  • Immediate, unlimited access to just this article
  • CME credits
  • AAFP app access
  • Print delivery available
Purchase Access:  Learn More

Continue Reading

More in AFP

More in Pubmed

Copyright © 2021 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.